Merchants Bancorp 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Merchants Bancorp (MBIN)
Reporting Period: Fiscal year ended December 31, 2024
Business Model: A diversified bank holding company operating through three primary segments: Multi-family Mortgage Banking (originating and servicing multi-family and healthcare loans), Mortgage Warehousing (funding residential and multi-family loans for non-depository institutions), and Banking (retail, commercial, agricultural, and SBA lending).
Key Developments: In January 2024, the company sold its Illinois branches and merged the remaining charter into Merchants Bank. The company executed significant capital management activities, including a common stock offering ($97.7M net proceeds), a Series E preferred stock offering ($222.7M net proceeds), and the redemption of Series A preferred stock ($52.0M). The company also utilized credit default swaps and securitizations to manage risk-weighted assets.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Net Income | $320.4 million | $279.2 million |
| Diluted EPS | $6.30 | $5.64 |
| Total Assets | $18.8 billion | $17.0 billion |
| Total Deposits | $11.9 billion | $14.1 billion |
| Loans Receivable (Net) | $10.4 billion | $10.1 billion |
| Net Interest Income | $522.6 million | $448.1 million |
| Noninterest Income | $148.1 million | $114.7 million |
| Noninterest Expense | $223.8 million | $174.6 million |
| Return on Average Assets (ROA) | 1.79% | 1.85% |
| Return on Average Equity (ROE) | 16.86% | 17.63% |
| Efficiency Ratio (Non-GAAP) | 33.37% | 31.03% |
| Net Interest Margin | 3.03% | 3.06% |
| Allowance for Credit Losses (ACL) | $84.4 million (0.81% of loans) | $71.8 million (0.70% of loans) |
| Nonperforming Loans | $279.7 million (2.68% of loans) | $82.0 million (0.80% of loans) |
Material Changes vs. Prior Period
- Profitability Growth: Net income increased 15% ($41.2 million) driven by a 17% increase in net interest income and a 29% increase in noninterest income. This was partially offset by a 28% increase in noninterest expenses.
- Asset Quality Deterioration: Nonperforming loans increased significantly from $82.0 million to $279.7 million (2.68% of total loans). This increase was primarily driven by multi-family and healthcare customers with variable-rate loans facing higher payments due to elevated interest rates. The ACL coverage ratio for nonperforming loans decreased from 87.5% to 30.2%.
- Deposit Shift: Total deposits decreased 15% to $11.9 billion. The company strategically reduced reliance on brokered deposits (down 58% to $2.5 billion) while growing core deposits by 16% to $9.4 billion.
- Expense Increase: Noninterest expense rose $49.2 million, largely due to higher FDIC insurance assessments (following the transition to "large bank" status with assets over $10 billion), increased salaries/commissions, and credit risk transfer premiums.
- Capital Management: The company raised significant capital through equity offerings and utilized securitizations (including a $628.9M healthcare loan securitization) to optimize capital ratios.
Guidance, Outlook, and Risks
Management Commentary: Management expects loan portfolio growth to continue in 2025, which may lead to an increase in the provision for credit losses. The company anticipates that credit quality will improve as interest rates decline, allowing loans currently on nonaccrual to return to accrual status after six months of performance. The company maintains a strong liquidity position with $4.3 billion in unused borrowing capacity.
Risks and Contingencies:
- Interest Rate Risk: The company is asset-sensitive; rising rates generally benefit net interest income, but the recent rise in nonperforming loans highlights the risk of borrower stress in a high-rate environment.
- Credit Risk: Concentration in multi-family and healthcare financing exposes the company to sector-specific economic downturns and interest rate sensitivity.
- Regulatory Risk: As a bank with assets exceeding $10 billion, the company faces heightened regulatory scrutiny, including direct examination by the CFPB and higher FDIC assessment rates.
- Liquidity Risk: While liquidity is strong, the company relies on a mix of core deposits, brokered deposits, and wholesale funding (FHLB/Fed). A significant outflow of brokered deposits could increase funding costs.
Key Facts for Investor Verification
- Nonperforming Loan Concentration: Verify the specific exposure to multi-family and healthcare borrowers driving the 2.68% nonperforming loan ratio and the adequacy of the 30% coverage ratio.
- FDIC Assessment Impact: Confirm the ongoing impact of the "large bank" classification on future FDIC insurance expense and profitability.
- Brokered Deposit Runoff: Monitor the trend of brokered deposits, which were reduced by $3.4 billion in 2024, and the cost of replacing this funding if core deposit growth slows.
- Capital Ratios: Verify that the company remains "well-capitalized" under Basel III standards despite the increase in risk-weighted assets from loan growth.
- Securitization Activity: Review the terms and ongoing servicing obligations related to the $628.9 million healthcare loan securitization and other credit risk transfer arrangements.